125 related articles for article (PubMed ID: 19692771)
1. [Survey of oxaliplatin-associated peripheral sensory neuropathy using an interview-based questionnaire in patients with advanced colorectal cancer].
Satomi M; Kono T; Mamiya N; Chisato N; Ebisawa Y; Sugawara M; Saito T; Matsubara K; Kasai S
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1321-5. PubMed ID: 19692771
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of a case of oxaliplatin - induced persistence sensory neuropathy].
Matsuo K; Higuchi M; Sasaki Y; Iwatsubo S; Wada Y; Hasegawa K; Shirakawa A; Mishima K; Iwasaki K; Fujiwara M; Nishino H
Gan To Kagaku Ryoho; 2010 Mar; 37(3):551-4. PubMed ID: 20332703
[TBL] [Abstract][Full Text] [Related]
3. Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.
Inoue N; Ishida H; Sano M; Kishino T; Okada N; Kumamoto K; Ishibashi K
Int J Clin Oncol; 2012 Aug; 17(4):341-7. PubMed ID: 21833683
[TBL] [Abstract][Full Text] [Related]
4. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Kono T
Int J Clin Oncol; 2011 Aug; 16(4):322-7. PubMed ID: 21258836
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
7. [Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer].
Matsuda M; Matsusaka S; Kuboki Y; Itimura T; Ogura M; Suenaga M; Syouji D; Watanabe C; Chin K; Mizunuma N; Hatake K
Gan To Kagaku Ryoho; 2008 Mar; 35(3):461-6. PubMed ID: 18347395
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin-safety profile: neurotoxicity.
Grothey A
Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
[TBL] [Abstract][Full Text] [Related]
10. [Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan].
Shindo Y; Tenma K; Imano H; Hibino M; Yoshino K; Nakamura M
Gan To Kagaku Ryoho; 2008 May; 35(5):863-5. PubMed ID: 18487931
[TBL] [Abstract][Full Text] [Related]
11. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
[TBL] [Abstract][Full Text] [Related]
12. Impact of oxaliplatin-induced neuropathy: a patient perspective.
Bennett BK; Park SB; Lin CS; Friedlander ML; Kiernan MC; Goldstein D
Support Care Cancer; 2012 Nov; 20(11):2959-67. PubMed ID: 22426503
[TBL] [Abstract][Full Text] [Related]
13. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
[TBL] [Abstract][Full Text] [Related]
14. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
15. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
[TBL] [Abstract][Full Text] [Related]
16. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer.
Choi J; Kong K; Mozaffar T; Holcombe RF
Anticancer Drugs; 2006 Jan; 17(1):103-5. PubMed ID: 16317297
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
Shimizu T; Satoh T; Tamura K; Ozaki T; Okamoto I; Fukuoka M; Nakagawa K
Int J Clin Oncol; 2007 Jun; 12(3):218-23. PubMed ID: 17566846
[TBL] [Abstract][Full Text] [Related]
18. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study.
von Delius S; Eckel F; Wagenpfeil S; Mayr M; Stock K; Kullmann F; Obermeier F; Erdmann J; Schmelz R; Quasthoff S; Adelsberger H; Bredenkamp R; Schmid RM; Lersch C
Invest New Drugs; 2007 Apr; 25(2):173-80. PubMed ID: 16983507
[TBL] [Abstract][Full Text] [Related]
19. [Promising effects of pregabalin in the treatment of oxaliplatin-induced sensory neuropathy in patients with colorectal carcinoma].
Nagahara H; Noda E; Maeda K; Inoue T; Hirakawa T; Hasegawa T; Shibutani M; Hirakawa K
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1181-3. PubMed ID: 24047775
[TBL] [Abstract][Full Text] [Related]
20. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
